Please Wait.....
Report
Global Ophthalmology Market - Industry Trends and Forecast to 2030
Market Report I 2022-12-01 I 718 Pages I Data Bridge Market Research
The global ophthalmology market is projected to register a substantial CAGR of 6.4 % in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.
Market Segmentation
Global Ophthalmology Market, By Product Type (Device, Drugs, and Others), Diseases (Glaucoma, Cataract, Age-Related Macular Degeneration, Inflammatory Diseases, Refractive Disorders, and Others), Prescription Mode (Generic, and Branded), Drug Type (Prescription, and Over the Counter (OTC)), Route of Administration (Oral, Topical, Injectables, Local Ocular, and Others) End User (Hospitals, Clinics, Home Healthcare, and Others), Distribution Channel (Direct Tender, Retail Sales and Others), Region (North America, Europe, Asia-Pacific, South America, Middle East and Africa), Industry Trends and Forecast to 2030.
Some of the major factors contributing to the growth of the global ophthalmology market are:
- Rising prevalence of ophthalmic disorders & ocular pains
- Increasing unhygienic & sedentary lifestyle
- The rise in traumatic injuries
- The rise in the geriatric population
Market Players:
Some of the key market players for the Global Ophthalmology market are listed below:
- Johnson & Johnson Services, Inc.
- Novartis AG
- Bausch & Lomb Incorporated
- AbbVie Inc.
- Alcon
- Santen Pharmaceutical Co., Ltd.
- Others.
TABLE OF CONTENTS
1 INTRODUCTION 84
1.1 OBJECTIVES OF THE STUDY 84
1.2 MARKET DEFINITION 84
1.3 OVERVIEW OF THE GLOBAL OPHTHALMOLOGY MARKET 84
1.4 CURRENCY AND PRICING 86
1.5 LIMITATIONS 87
1.6 MARKETS COVERED 87
2 GLOBAL OPHTHALMOLOGY MARKET: SEGMENTATION 93
2.1 MARKETS COVERED 93
2.2 GEOGRAPHICAL SCOPE 94
2.3 YEARS CONSIDERED FOR THE STUDY 95
2.4 DBMR TRIPOD DATA VALIDATION MODEL 96
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 99
2.6 MULTIVARIATE MODELLING 100
2.7 PRODUCT SEGMENT LIFELINE CURVE 100
2.8 DBMR MARKET POSITION GRID 101
2.9 VENDOR SHARE ANALYSIS 103
2.10 MARKET END USER COVERAGE GRID 104
2.11 SECONDARY SOURCES 105
3 EXECUTIVE SUMMARY 106
4 PREMIUM INSIGHTS 110
4.1 PESTEL ANALYSIS 112
4.2 PORTER'S FIVE FORCES 113
5 EPIDEMIOLOGY 114
6 STRATEGIC INITIATIVES 115
7 GLOBAL OPHTHALMOLOGY MARKET, REGULATION 116
8 MARKET OVERVIEW 119
8.1 DRIVERS 121
8.1.1 RISING PREVALENCE OF OPHTHALMIC DISORDERS & OCULAR PAINS 121
8.1.2 INCREASING UNHYGIENIC & SEDENTARY LIFESTYLE 121
8.1.3 RISE IN TRAUMATIC INJURIES 122
8.1.4 RISE IN THE GERIATRIC POPULATION 122
8.2 RESTRAINTS 123
8.2.1 HIGH COST & RISKS ASSOCIATED WITH EYE SURGERY & TREATMENT 123
8.2.2 LACK OF HEALTH INSURANCE AMONGST THE POPULATION, ESPECIALLY WITHIN THE DEVELOPING COUNTRIES 123
8.2.3 SIDE EFFECTS ASSOCIATED WITH TREATMENT DRUGS 124
8.3 OPPORTUNITIES 125
8.3.1 RISE IN HEALTHCARE EXPENDITURE AND DISPOSABLE INCOME 125
8.3.2 STRATEGIC INITIATIVES BY KEY MARKET PLAYERS 125
8.3.3 RISING AWARENESS TO PREVENT THE BURDEN OF EYE DISEASES 126
8.4 CHALLENGE 127
8.4.1 LACK OF SKILLED PROFESSIONALS 127
8.4.2 STRINGENT RULES & REGULATIONS FOR PRODUCT APPROVAL 127
9 GLOBAL OPHTHALMOLOGY MARKET, BY PRODUCTS 129
9.1 OVERVIEW 130
9.2 DEVICE 133
9.2.1 SURGICAL DEVICE 134
9.2.1.1 CATARACT SURGICAL DEVICES 134
9.2.1.2 OPHTHALMIC VISCOELASTIC DEVICES 134
9.2.1.2.1 PHACOEMULSIFICATION DEVICES 135
9.2.1.2.2 CATARACT SURGICAL LASERS 135
9.2.1.2.3 IOL INJECTORS 135
9.2.1.3 VITREORETINAL SURGICAL DEVICES 135
9.2.1.3.1 VITREORETINAL PACKS 135
9.2.1.3.2 VITRECTOMY MACHINES 135
9.2.1.3.3 VITRECTOMY PROBES 136
9.2.1.3.4 PHOTOCOAGULATION LASERS 136
9.2.1.3.5 ILLUMINATION DEVICES 136
9.2.1.4 REFRACTIVE SURGICAL DEVICES 136
9.2.1.4.1 FEMTOSECOND LASERS 136
9.2.1.4.2 EXCIMER LASERS 136
9.2.1.4.3 OTHER REFRACTIVE SURGICAL LASERS 136
9.2.1.5 GLAUCOMA SURGICAL DEVICES 137
9.2.1.5.1 GLAUCOMA DRAINAGE DEVICES 137
9.2.1.5.2 GLAUCOMA LASER SYSTEMS 137
9.2.1.5.3 MICRO INVASIVE GLAUCOMA SURGERY DEVICES 137
9.2.2 DIAGNOSTIC DEVICE 138
9.2.2.1 AUTOREFRACTORS & KERATOMETERS 138
9.2.2.2 TONOMETER 138
9.2.2.3 PHOROPTERS 139
9.2.2.4 RETINOSCOPES 139
9.2.2.5 OPHTHALMOSCOPES 139
9.2.2.6 PERIMETERS/VISUAL FIELD ANALYZERS 139
9.2.2.7 OPHTHALMIC ULTRASOUND IMAGING SYSTEMS 139
9.2.2.7.1 A- SCAN IMAGING SYSTEM 139
9.2.2.7.2 B-SCAN IMAGING SYSTEM 139
9.2.2.7.3 PACHYMETERS 140
9.2.2.7.4 ULTRASOUND BIOMICROSCOPES 140
9.2.2.8 LENSMETERS 140
9.2.2.9 CORNEAL TOPOGRAPHY SYSTEMS 140
9.2.2.10 OPTICAL COHERENCE TOMOGRAPHY SCANNERS 140
9.2.2.11 FUNDUS CAMERAS 140
9.2.2.12 OPTICAL BIOMETRY SYSTEMS 140
9.2.2.13 SPECULAR MICROSCOPES 140
9.2.2.14 WAVEFRONT ABERROMETERS 140
9.2.2.15 CHART PROJECTORS 140
9.2.2.16 SLIT LAMPS 140
9.2.3 OPHTHALMIC SURGICAL ACCESSORIES 141
9.2.3.1 SURGICAL INSTRUMENTS & KITS 141
9.2.3.2 OPHTHALMIC FORCEPS 141
9.2.3.3 OPHTHALMIC SPATULA 141
9.2.3.4 OPHTHALMIC TIPS AND HANDLES 141
9.2.3.5 OPHTHALMIC CANNULAS 141
9.2.3.6 OPHTHALMIC SCISSORS 142
9.2.3.7 OTHERS SURGICAL ACCESSORIES 142
9.2.4 OPHTHALMIC MICROSCOPES 142
9.3 DRUGS 142
9.3.1 ANTI-INFLAMMATION DRUGS 143
9.3.1.1 NON-STEROIDAL ANTI-INFLAMMATORY DRUGS 143
9.3.1.2 STEROIDAL ANTI-INFLAMMATORY DRUGS 143
9.3.2 ALLERGIC CONJUNCTIVITIS 144
9.3.3 DRY EYE DRUGS 144
9.3.4 RETINAL DISORDER DRUGS 144
9.3.5 ANTI-GLAUCOMA DRUGS 144
9.3.5.1 MIOTICS 144
9.3.5.1.1 PILOCARPINE 145
9.3.5.1.2 ESERINE 145
9.3.5.2 BETA ADRENERGIC ANTAGONISTS 145
9.3.5.2.1 TIMOLAL MALEATE 145
9.3.5.2.2 BETAXOLOL 145
9.3.5.3 PROSTAGLANDIN ANALOGS 146
9.3.5.3.1 LATANOPROST 146
9.3.5.3.2 BIMATOPROST 146
9.3.5.3.3 TRAVOPROST 146
9.3.5.3.4 TAFLUPROST 146
9.3.5.3.5 LATANOPROSTENE 146
9.3.5.4 ALPHA ADRENERGIC AGONISTS 147
9.3.5.4.1 EPINEPHRINE 147
9.3.5.4.2 DEPIVEPRINE 147
9.3.5.5 ANTI-VEGF DRUGS 147
9.3.5.5.1 RANIBIZUMAB 147
9.3.5.5.2 BEVACIZUMAB 148
9.3.6 OTHERS 148
9.4 OTHERS 148
9.4.1 VISION CARE PRODUCTS 149
9.4.1.1 SPECTACLES 149
9.4.1.2 CONTACT LENSES 149
9.4.1.2.1 SOFT CONTACT LENSES 149
9.4.1.2.2 HYBRID CONTACT LENSES 150
9.4.1.2.3 RIGID GAS PERMEABLE LENSES 150
9.4.2 OTHERS 150
10 GLOBAL OPHTHALMOLOGY MARKET, BY DISEASES 151
10.1 OVERVIEW 152
10.2 INFLAMMATORY DISEASES 155
10.3 CATARACT 156
10.4 REFRACTIVE DISORDERS 157
10.5 GLAUCOMA 158
10.6 AGE-RELATED MACULAR DEGENERATION 159
10.7 OTHERS 160
11 GLOBAL OPHTHALMOLOGY MARKET, BY PRESCRIPTION MODE 161
11.1 OVERVIEW 162
11.2 BRANDED 165
11.3 GENERIC 166
12 GLOBAL OPHTHALMOLOGY MARKET, BY DRUG TYPE 167
12.1 OVERVIEW 168
12.2 OVER THE COUNTER 171
12.3 PRESCRIPTION 172
13 GLOBAL OPHTHALMOLOGY MARKET, BY ROUTE OF ADMINISTRATION 173
13.1 OVERVIEW 174
13.2 TOPICAL 177
13.2.1 EYE DROPS 178
13.2.2 EYE SOLUTION 178
13.2.3 CREAM & OINTMENTS 178
13.2.4 GEL 178
13.2.5 OTHERS 178
13.3 ORAL 178
13.3.1 TABLET 179
13.3.2 CAPSULES 179
13.3.3 OTHERS 179
13.4 LOCAL OCULAR 179
13.4.1 SUBCONJUNCTIVAL 180
13.4.2 INTRAVITREAL 180
13.4.3 RETROBULBAR 180
13.4.4 INTRACAMERAL 180
13.5 INJECTABLE 181
13.5.1 INTRAMUSCULAR 181
13.5.2 INTRAVENOUS 182
13.5.3 OTHERS 182
13.6 OTHERS 182
14 GLOBAL OPHTHALMOLOGY MARKET, BY END USER 183
14.1 OVERVIEW 184
14.2 CLINICS 187
14.3 HOSPITALS 187
14.4 HOMECARE SETTINGS 188
14.5 OTHERS 189
15 GLOBAL OPHTHALMOLOGY MARKET, BY DISTRIBUTION CHANNEL 190
15.1 OVERVIEW 191
15.2 RETAIL SALES 194
15.2.1 RETAIL SHOPS 194
15.2.2 HOSPITAL PHARMACY 195
15.2.3 ONLINE PHARMACY 195
15.3 DIRECT TENDER 195
15.4 OTHERS 196
16 GLOBAL OPHTHALMOLOGY MARKET, BY GEOGRAPHY 197
16.1 OVERVIEW 198
16.2 NORTH AMERICA 204
16.2.1 U.S. 219
16.2.2 CANADA 229
16.2.3 MEXICO 239
16.3 EUROPE 249
16.3.1 GERMANY 264
16.3.2 U.K. 273
16.3.3 FRANCE 283
16.3.4 HUNGARY 293
16.3.5 LITHUANIA 303
16.3.6 AUSTRIA 313
16.3.7 IRELAND 323
16.3.8 NORWAY 332
16.3.9 POLAND 341
16.3.10 ITALY 350
16.3.11 SPAIN 360
16.3.12 RUSSIA 369
16.3.13 TURKEY 378
16.3.14 NETHERLANDS 387
16.3.15 SWITZERLAND 397
16.3.16 REST OF EUROPE 407
16.4 ASIA-PACIFIC 408
16.4.1 CHINA 424
16.4.2 JAPAN 434
16.4.3 INDIA 444
16.4.4 AUSTRALIA 454
16.4.5 SOUTH KOREA 464
16.4.6 THAILAND 474
16.4.7 SINGAPORE 484
16.4.8 INDONESIA 494
16.4.9 MALAYSIA 504
16.4.10 PHILIPPINES 514
16.4.11 VIETNAM 524
16.4.12 REST OF ASIA-PACIFIC 534
16.5 SOUTH AMERICA 535
16.5.1 BRAZIL 551
16.5.2 ARGENTINA 561
16.5.3 PERU 571
16.5.4 REST OF SOUTH AMERICA 581
16.6 MIDDLE EAST AND AFRICA 582
16.6.1 SOUTH AFRICA 598
16.6.2 SAUDI ARABIA 608
16.6.3 U.A.E. 618
16.6.4 EGYPT 628
16.6.5 KUWAIT 638
16.6.6 ISRAEL 648
16.6.7 REST OF MIDDLE EAST AND AFRICA 658
17 GLOBAL OPHTHALMOLOGY MARKET: COMPANY LANDSCAPE 659
17.1 COMPANY SHARE ANALYSIS: GLOBAL 659
17.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 660
17.3 COMPANY SHARE ANALYSIS: EUROPE 661
17.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 662
18 SWOT ANALYSIS 663
19 COMPANY PROFILE 664
19.1 ALCON 664
19.1.1 COMPANY SNAPSHOT 664
19.1.2 RECENT FINANCIALS 665
19.1.3 COMPANY SHARE ANALYSIS 665
19.1.4 PRODUCT PORTFOLIO 666
19.1.5 RECENT DEVELOPMENTS 666
19.2 REGENERON PHARMACEUTICALS INC. 668
19.2.1 COMPANY SNAPSHOT 668
19.2.2 RECENT FINANCIALS 668
19.2.3 COMPANY SHARE ANALYSIS 669
19.2.4 PRODUCT PORTFOLIO 669
19.2.5 RECENT DEVELOPMENT 669
19.3 JOHNSON & JOHNSON SERVICES, INC. 670
19.3.1 COMPANY SNAPSHOT 670
19.3.2 RECENT FINANCIALS 670
19.3.3 COMPANY SHARE ANALYSIS 671
19.3.4 PRODUCT PORTFOLIO 671
19.3.5 RECENT DEVELOPMENT 671
19.4 REICHERT, INC. 672
19.4.1 COMPANY SNAPSHOT 672
19.4.2 COMPANY SHARE ANALYSIS 672
19.4.3 PRODUCT PORTFOLIO 673
19.4.4 RECENT DEVELOPMENT 673
19.5 NOVARTIS AG 674
19.5.1 COMPANY SNAPSHOT 674
19.5.2 REVENUE ANALYSIS 674
19.5.3 COMPANY SHARE ANALYSIS 675
19.5.4 PRODUCT PORTFOLIO 675
19.5.5 RECENT DEVELOPMENTS 675
19.6 ABBVIE INC. 676
19.6.1 COMPANY SNAPSHOT 676
19.6.2 RECENT FINANCIALS 676
19.6.3 PRODUCT PORTFOLIO 677
19.6.4 RECENT DEVELOPMENT 677
19.7 BAUSCH & LOMB INCORPORATED 678
19.7.1 COMPANY SNAPSHOT 678
19.7.2 REVENUE ANALYSIS 678
19.7.3 PRODUCT PORTFOLIO 679
19.7.4 RECENT DEVELOPMENTS 679
19.8 CARL ZEISS MEDITEC AG 681
19.8.1 COMPANY SNAPSHOT 681
19.8.2 REVENUE ANALYSIS 681
19.8.3 PRODUCT PORTFOLIO 682
19.8.4 RECENT DEVELOPMENTS 682
19.9 ESSILORLUXOTTICA 683
19.9.1 COMPANY SNAPSHOT 683
19.9.2 REVENUE ANALYSIS 683
19.9.3 PRODUCT PORTFOLIO 684
19.9.4 RECENT DEVELOPMEN 684
19.10 F. HOFFMANN- LA ROCHE LTD 685
19.10.1 COMPANY SNAPSHOT 685
19.10.2 REVENUE ANALYSIS 685
19.10.3 PRODUCT PORTFOLIO 686
19.10.4 RECENT DEVELOPMENT 686
19.11 GLAUKOS 687
19.11.1 COMPANY SNAPSHOT 687
19.11.2 REVENUE ANALYSIS 687
19.11.3 PRODUCT PORTFOLIO 688
19.11.4 RECENT DEVELOPMENTS 688
19.12 HEIDELBERG ENGINEERING GMBH 689
19.12.1 COMPANY SNAPSHOT 689
19.12.2 PRODUCT PORTFOLIO 689
19.12.3 RECENT DEVELOPMENT 689
19.13 HOYA CORPORATION 690
19.13.1 COMPANY SNAPSHOT 690
19.13.2 REVENUE ANALYSIS 690
19.13.3 PRODUCT PORTFOLIO 691
19.13.4 RECENT DEVELOPMENTS 691
19.14 LUMENIS BE LTD. 692
19.14.1 COMPANY SNAPSHOT 692
19.14.2 PRODUCT PORTFOLIO 692
19.14.3 RECENT DEVELOPMENT 693
19.15 METALL ZUG AG 694
19.15.1 COMPANY SNAPSHOT 694
19.15.2 REVENUE ANALYSIS 694
19.15.3 PRODUCT PORTFOLIO 695
19.15.4 RECENT DEVELOPMENT 695
19.16 NEOVISION 696
19.16.1 COMPANY SNAPSHOT 696
19.16.2 PRODUCT PORTFOLIO 696
19.16.3 RECENT DEVELOPMENT 696
19.17 NIDEK CO., LTD. 697
19.17.1 COMPANY SNAPSHOT 697
19.17.2 PRODUCT PORTFOLIO 697
19.17.3 RECENT DEVELOPMENT 698
19.18 PFIZER INC. 699
19.18.1 COMPANY SNAPSHOT 699
19.18.2 REVENUE ANALYSIS 699
19.18.3 PRODUCT PORTFOLIO 700
19.18.4 RECENT DEVELOPMENT 700
19.19 SANTEN PHARMACEUTICAL CO., LTD. 701
19.19.1 COMPANY SNAPSHOT 701
19.19.2 RECENT FINANCIALS 701
19.19.3 PRODUCT PORTFOLIO 702
19.19.4 RECENT DEVELOPMENTS 702
19.20 SUN PHARMACEUTICAL INDUSTRIES LTD. 703
19.20.1 COMPANY SNAPSHOT 703
19.20.2 RECENT FINANCIALS 703
19.20.3 PRODUCT PORTFOLIO 704
19.20.4 RECENT DEVELOPMENTS 704
19.21 STAAR SURGICAL 705
19.21.1 COMPANY SNAPSHOT 705
19.21.2 REVENUE ANALYSIS 705
19.21.3 PRODUCT PORTFOLIO 706
19.21.4 RECENT DEVELOPMENTS 706
19.22 THE COOPER COMPANIES INC. 707
19.22.1 COMPANY SNAPSHOT 707
19.22.2 REVENUE ANALYSIS 707
19.22.3 PRODUCT PORTFOLIO 708
19.22.4 RECENT DEVELOPMENTS 708
19.23 TOPCON CORPORATION 709
19.23.1 COMPANY SNAPSHOT 709
19.23.2 REVENUE ANALYSIS 709
19.23.3 PRODUCT PORTFOLIO 710
19.23.4 RECENT DEVELOPMENTS 710
19.24 VISIONIX 711
19.24.1 COMPANY SNAPSHOT 711
19.24.2 PRODUCT PORTFOLIO 711
19.24.3 RECENT DEVELOPMENT 711
19.25 ZIEMER OPHTHALMIC SYSTEMS AG 712
19.25.1 COMPANY SNAPSHOT 712
19.25.2 PRODUCT PORTFOLIO 712
19.25.3 RECENT DEVELOPMENTS 713
20 QUESTIONNAIRE 714
21 RELATED REPORTS 718
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security